Adding irinotecan to first-line gemcitabine improves tumour response in advanced pancreatic cancer: Abstracted from: Rocha Lima CM, Green MR, Rotche R et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumour response rate. J Clin Oncol 2004;22:3776–83.

✍ Scribed by Desmond Yip; David Goldstein

• Book ID: 116394953
• Publisher: Elsevier Science
• Year: 2005
• Tongue: English
• Weight: 103 KB
• Volume: 31
• Category: Article
• ISSN: 0305-7372
• DOI: 10.1016/j.ctrv.2005.03.003